Furthermore, lower CD4+-T-cells are known to be a risk factor for the development of herpes zoster virus reactivation in MM patients receiving bortezomib, as well as for opportunistic infections in patients with MM receiving conventional therapy (6, 28). The gene discussed is CD4; the disease is Miyoshi myopathy.